Researchers at Yale Cancer Center showed that inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing.
Reduced screening rates and a higher prevalence of triple-negative breast cancer are driving elevated rates of advanced breast cancer in a geographic hotspot in Wilmington, Delaware, according to findings by researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute.
